The infant case-control validation study has been designed in close collaboration with Work Package (WP) 4 partners. This monocenter study will take place at UMC Utrecht. The protocol and additional documentation have been approved by the UMC Utrecht Institutional Review Board.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.
© 2023 | IMI-Promise
